NUP98 fusion partner genes and characteristics
| Fusion partner . | Chr. . | HOX gene? . | Transcription-related domain/function . | Disease . | Ref. . |
|---|---|---|---|---|---|
| ADD3 | 10q25 | No | None identified | Therapy-related AML, T-ALL | 152 |
| ANKRD28 | 3p25 | No | None identified | MDS/AML | 153 |
| BPTF | 17q24 | No | PHD domain | T-ALL, AML | 45 |
| CCD28A (C6orf80) | 6q24 | No | None identified | AML, T-ALL | 154 |
| DDX10 | 11q22 | No | RNA helicase, involved in ribosome assembly | De novo or therapy-related MDS and AML, CML, CMML | 22 |
| GSX2 | 4q12 | Yes | HOX | AML | 40 |
| HHEX | 10q23 | Yes | HOX | AML | 39 |
| HMGB3 | Xq28 | No | Nucleosome remodeling (HMG box) | Therapy-related AML | 79 |
| HOXA9 | 7p15 | Yes | HOX | De novo or therapy-related AML, MDS, CML, CMML | 20,21 |
| HOXA11 | 7p15 | Yes | HOX | CML, JMML | 24 |
| HOXA13 | 7p15 | Yes | HOX | De novo AML, MDS, CML, CMML | 24 |
| HOXC11 | 12q13 | Yes | HOX | De novo or therapy-related AML | 35 |
| HOXC13 | 12q13 | Yes | HOX | De novo or therapy-related AML | 155 |
| HOXD11 | 2p31 | Yes | HOX | De novo AML | 37 |
| HOXD13 | 2p31 | Yes | HOX | De novo or therapy-related AML, CML | 38 |
| IQCG | 3q29 | No | None identified | MPAL | 29 |
| JADE2 | 5p31 | No | PHD domain | JMML | 46 |
| KAT7 (HBO1) | 17q21 | No | HAT | CMML | 52 |
| KDM5A (JARID1A) | 12p13 | No | PHD domain, H3K4 demethylation | AML | 47 |
| LNP1 | 3q12 | No | None identified | AML | 156 |
| KMT2A (MLL) | 11q23 | No | H3K4 methyltransferase | AML | 51 |
| MLLT10 (AF10) | 10p12 | No | OM-LZ domain, putative transcription factor | Atypical MDS resembling CMML | 40 |
| NSD1 | 5q35 | No | SET and PHD domains | MDS, AML, MPAL | 48 |
| NSD3 | 8p11 | No | SET and PHD domains | MDS, de novo or therapy-related AML | 49 |
| PHF23 | 17p13 | No | PHD domain | AML | 50 |
| PRRX1 | 1q24 | Yes | HOX | AML, CML, therapy-related MDS | 41 |
| PRRX2 | 9q34 | Yes | HOX | Therapy-related AML | 42 |
| POU1F1 | 3p11 | Yes | HOX | Therapy-related AML | 43 |
| PSIP1 (LEDGF) | 9p22 | No | Transcriptional coactivator | AML, CML, MDS | 53 |
| RAP1GDS1 | 4q23 | No | None identified–G-protein signaling | T-ALL, AML | 26 |
| RARA | 17q21 | No | DNA-binding domain | AML | 157 |
| RARG | 12q13 | No | DNA-binding domain | AML | 158 |
| SETBP1 | 18q12 | No | SET-binding protein | T-ALL | 27 |
| TOP1 | 20q12 | No | Topoisomerase | MDS, AML | 159 |
| TOP2B | 3p24 | No | Topoisomerase | De novo AML | 160 |
| VRK1 | 14q32 | No | None identified | T-ALL | 161 |
| Fusion partner . | Chr. . | HOX gene? . | Transcription-related domain/function . | Disease . | Ref. . |
|---|---|---|---|---|---|
| ADD3 | 10q25 | No | None identified | Therapy-related AML, T-ALL | 152 |
| ANKRD28 | 3p25 | No | None identified | MDS/AML | 153 |
| BPTF | 17q24 | No | PHD domain | T-ALL, AML | 45 |
| CCD28A (C6orf80) | 6q24 | No | None identified | AML, T-ALL | 154 |
| DDX10 | 11q22 | No | RNA helicase, involved in ribosome assembly | De novo or therapy-related MDS and AML, CML, CMML | 22 |
| GSX2 | 4q12 | Yes | HOX | AML | 40 |
| HHEX | 10q23 | Yes | HOX | AML | 39 |
| HMGB3 | Xq28 | No | Nucleosome remodeling (HMG box) | Therapy-related AML | 79 |
| HOXA9 | 7p15 | Yes | HOX | De novo or therapy-related AML, MDS, CML, CMML | 20,21 |
| HOXA11 | 7p15 | Yes | HOX | CML, JMML | 24 |
| HOXA13 | 7p15 | Yes | HOX | De novo AML, MDS, CML, CMML | 24 |
| HOXC11 | 12q13 | Yes | HOX | De novo or therapy-related AML | 35 |
| HOXC13 | 12q13 | Yes | HOX | De novo or therapy-related AML | 155 |
| HOXD11 | 2p31 | Yes | HOX | De novo AML | 37 |
| HOXD13 | 2p31 | Yes | HOX | De novo or therapy-related AML, CML | 38 |
| IQCG | 3q29 | No | None identified | MPAL | 29 |
| JADE2 | 5p31 | No | PHD domain | JMML | 46 |
| KAT7 (HBO1) | 17q21 | No | HAT | CMML | 52 |
| KDM5A (JARID1A) | 12p13 | No | PHD domain, H3K4 demethylation | AML | 47 |
| LNP1 | 3q12 | No | None identified | AML | 156 |
| KMT2A (MLL) | 11q23 | No | H3K4 methyltransferase | AML | 51 |
| MLLT10 (AF10) | 10p12 | No | OM-LZ domain, putative transcription factor | Atypical MDS resembling CMML | 40 |
| NSD1 | 5q35 | No | SET and PHD domains | MDS, AML, MPAL | 48 |
| NSD3 | 8p11 | No | SET and PHD domains | MDS, de novo or therapy-related AML | 49 |
| PHF23 | 17p13 | No | PHD domain | AML | 50 |
| PRRX1 | 1q24 | Yes | HOX | AML, CML, therapy-related MDS | 41 |
| PRRX2 | 9q34 | Yes | HOX | Therapy-related AML | 42 |
| POU1F1 | 3p11 | Yes | HOX | Therapy-related AML | 43 |
| PSIP1 (LEDGF) | 9p22 | No | Transcriptional coactivator | AML, CML, MDS | 53 |
| RAP1GDS1 | 4q23 | No | None identified–G-protein signaling | T-ALL, AML | 26 |
| RARA | 17q21 | No | DNA-binding domain | AML | 157 |
| RARG | 12q13 | No | DNA-binding domain | AML | 158 |
| SETBP1 | 18q12 | No | SET-binding protein | T-ALL | 27 |
| TOP1 | 20q12 | No | Topoisomerase | MDS, AML | 159 |
| TOP2B | 3p24 | No | Topoisomerase | De novo AML | 160 |
| VRK1 | 14q32 | No | None identified | T-ALL | 161 |
Chr., chromosome; CMML, chronic myelomonocytic leukemia; HAT, histone acetyltransferase; HMG, high-mobility group; JMML, juvenile myelomonocytic leukemia; MPN, myeloproliferative neoplasm; OM-LZ, octapeptide motif leucine zipper; Ref., reference.